AM-Pharma is a Dutch clinical-stage biopharmaceutical company focused on the development of ilofotase alfa, a proprietary recombinant human Alkaline Phosphatase (AP) therapeutic. This innovative enzyme-based treatment is being investigated for severe inflammatory diseases with high unmet medical needs, primarily Sepsis-associated Acute Kidney Injury (SA-AKI). AM-Pharma is also exploring its potential in Ulcerative Colitis. The company aims to significantly improve patient outcomes in critical care settings through its novel therapeutic approach.
The headquarters serves as the primary center for AM-Pharma's corporate management, research and development strategy, clinical trial oversight, and operational activities.
Situated in a region known for its concentration of biotech companies and research institutions, likely near the Utrecht Science Park. The facility is equipped for advanced biopharmaceutical research and corporate operations.
AM-Pharma fosters a science-driven, innovative, and collaborative work environment. Employees are typically focused on a mission to address critical unmet medical needs, emphasizing teamwork, expertise, and a commitment to rigorous scientific standards.
The Dutch headquarters is central to AM-Pharma's global strategy, coordinating international clinical trials, R&D collaborations, and strategic partnerships. Its location provides access to skilled talent and a supportive infrastructure for life sciences.
AM-Pharma operates with a global focus, particularly in its clinical development programs. The company conducts multinational clinical trials for ilofotase alfa, involving sites across North America, Europe, and other regions. While its main R&D and corporate functions are in the Netherlands and the US, its operational reach for patient recruitment, trial management, and regulatory engagement is international, collaborating with various Contract Research Organizations (CROs) and clinical centers worldwide.
Rumpsterweg 6
Bunnik
Utrecht
Netherlands
Address: 101 Carnegie Center, Suite 105, Princeton, NJ 08540
To facilitate engagement with the U.S. Food and Drug Administration (FDA), manage clinical trial sites, connect with U.S.-based investigators and key opinion leaders, and support business development activities in the North American market.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AM-Pharma' leadership includes:
AM-Pharma has been backed by several prominent investors over the years, including:
AM-Pharma has maintained a stable core executive team over the past 12 months (mid-2023 to mid-2024), with no major publicly announced hires or departures at the C-suite level. The existing leadership continues to guide the company through its critical late-stage clinical trials and towards potential commercialization.
Discover the tools AM-Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
AM-Pharma's email addresses typically follow common corporate patterns using the company domain '@am-pharma.com'. The most probable formats involve combinations of employee first and last names.
[firstinitial][lastname]@am-pharma.com
Format
evandenberg@am-pharma.com
Example
75%
Success rate
am-pharma.com • May 2, 2024
AM-Pharma confirmed the completion of patient enrollment for its REVIVAL Phase III clinical trial. This pivotal study evaluates the efficacy and safety of ilofotase alfa in treating patients with Sepsis-associated Acute Kidney Injury (SA-AKI). The company anticipates reporting topline results in the second half of 2024....more
am-pharma.com • January 10, 2024
AM-Pharma announced an upsized Series F financing round, reaching a total of €47 million (approximately US$ 51 million). This included an additional €25 million investment from the European Innovation Council (EIC) Fund, aimed at supporting the late-stage clinical development of ilofotase alfa and pre-commercialization activities....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AM-Pharma, are just a search away.